Q1 2028
Ends Mar 31, 2028
Revenue
$1.10T
$1.08T to $1.13T
EPS
49.53
48.14 to 50.93
No analyst count
EPS: No analyst count
May 2, 07:40 AM UTC
stable/analyst-estimates
Healthcare
Live Price
Offline$15.63
+1.36% today
1Y Change
+3.43%
Window
Jun 23, 2025 → Jun 1, 2026
Coverage: 237 bars · Jun 23, 2025 → Jun 1, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Takeda Pharmaceutical Company Limited (TAK) is a Healthcare stock with a market cap of $8.28T and listed on NYSE. The stock last traded around $15.63 and up 3.4% across the available one-year price window (Jun 23, 2025 → Jun 1, 2026). Baseline metrics include revenue growth of +7.5%, EPS growth of -25.8%, a dividend yield of 3.8%. What stands out right now is revenue +7.5%, EPS -25.8%, free cash flow +263.5% with operating margin 10.3% and ROIC 1.9%. The dividend matters to the case here, with a current yield around 3.8%. Valuation already assumes a fairly strong business story at P/E 73.3 and price/sales 1.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TAK price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TAK
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TAK Max Drawdown
-19.02%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TAK and SPY.
EPS Consensus
49.53
Range 48.14 → 50.93
No analyst count
vs prior: -24.6%Revenue Outlook
$1.10T
Range $1.08T → $1.13T
No analyst count
vs prior: -5.3%Consensus Spread
Lower spread suggests tighter agreement across covering analysts.
Trend
Consensus average across visible periods
Trend
Average analyst revenue estimate
Timeline
Sorted by period end date. Includes both cached rows and live fallbacks from FMP.
Next Step
Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.